A new observational cohort study based on data from Stockholm, Sweden found that women were less likely to receive a CKD diagnosis, visit a nephrologist, have their creatinine and albuminuria measured, or to receive guideline-recommended therapies. Differences in comorbidity did not explain these discrepancies and were similar among high-risk groups, among patients with evidence-based indications for medications, and among patients with confirmed CKD at retesting. Efforts to improve and ensure equitable health care between the sexes could have important implications for justice and could reduce the burden of CKD.